10-Q quarterly report · filed Nov 9, 2026

Praxis Precision Medicines, Inc. (PRAX) Q3 2026 10-Q Quarterly Report

Short answer

Praxis Precision Medicines, Inc. (PRAX) filed its Q3 2026 10-Q quarterly report on Nov 9, 2026 for the quarter ended Sep 30, 2026.

Q3 2026 key financials · XBRL

Net income
−$94M
−27.5% YoY · −12.6% QoQ
EPS (diluted)
−$3.23
+4.2% YoY · −12.2% QoQ

Source: XBRL data from the Praxis Precision Medicines, Inc. (PRAX) Q3 2026 10-Q on SEC EDGAR. USD.

Praxis Precision Medicines, Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Revenue $0, unchanged YoY, no product sales since inception
  • Net loss $94.2M vs $73.9M YoY, operating loss $106.9M vs $78.4M
  • R&D $64.2M vs $65.8M, Cerebrum™ highest at $40.4M, Solidus™ $2.8M
  • Cash, equivalents and marketable securities $1.3B, operating cash use $245.4M for nine months
  • Ulixacaltamide PDUFA January 29, 2027, relutrigine updated to December 27, 2026, POWER1 endpoint failure headwind

Risk Factors

  • No material changes from the December 31, 2025 Form 10-K risk factors
  • Carried-forward risks include clinical development, regulatory approval, commercialization, financing, competition, and intellectual property challenges

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Praxis Precision Medicines, Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.